Determinants of non‐compliance with lipid‐lowering therapy in hyperlipidemic patients
- 4 July 2002
- journal article
- research article
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 11 (7) , 593-600
- https://doi.org/10.1002/pds.730
Abstract
Purpose In order to assess the determinants of non-compliance with a lipid-lowering therapy, a prospective study of the hyperlipidemic Korean subjects was carried out. Methods A total of 1019 patients was observed by 46 family physicians for the period of 1 year from January 1999 to January 2000. To ascertain the compliance associated with a lipid lowering drug (Simvastatin), we regularly followed up the hyperlipidemic patients at intervals of 4, 12 and 24 weeks. The criterion for evaluating compliance is to measure clinic attendance. Using a structured questionnaire, patients and physicians were asked about risk factors for the compliance. Results During the first 24 weeks of treatment, the lipid-lowering medication was continued by 52.3% and discontinued by 19.7%. The remaining 28% dropped out. Patient-related factors for non-compliance were young age, current smoker, lack of low fat diet and exercise, new user, no concomitant medication, and occurrence of adverse reactions. Physician-related factors for non-compliance were low patients' satisfaction with the physician, small number of hyperlipidemic patients per month and working in a relatively small hospital. Conclusions Compliance with the lipid-lowering therapy was relatively low and several factors for non-compliance were detected. Copyright © 2002 John Wiley & Sons, Ltd.Keywords
This publication has 19 references indexed in Scilit:
- Factors associated with low compliance with lipid-lowering drugs in hyperlipidemic patientsJournal of Clinical Pharmacy & Therapeutics, 2000
- Effects of pravastatin in 3260 patients with unstable angina: results from the LIPID studyThe Lancet, 2000
- Lack of adherence to lipid‐lowering drug treatment. A comparison of utilization patterns in defined populations in Funen, Denmark and Bologna, ItalyBritish Journal of Clinical Pharmacology, 2000
- Persistence of Use of Lipid-Lowering MedicationsJAMA, 1998
- Compliance and adverse event withdrawal: their impact on the West of Scotland Coronary Prevention StudyEuropean Heart Journal, 1997
- The problem of compliance to cholesterol altering therapyJournal of Internal Medicine, 1997
- Prevention of Coronary Heart Disease with Pravastatin in Men with HypercholesterolemiaNew England Journal of Medicine, 1995
- Discontinuation of Antihyperlipidemic Drugs — Do Rates Reported in Clinical Trials Reflect Rates in Primary Care Settings?New England Journal of Medicine, 1995
- Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with DyslipidemiaNew England Journal of Medicine, 1987
- Influence of Adherence to Treatment and Response of Cholesterol on Mortality in the Coronary Drug ProjectNew England Journal of Medicine, 1980